Buprenorphine for Prisoners

PHASE3CompletedINTERVENTIONAL
Enrollment

213

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

March 31, 2013

Study Completion Date

November 30, 2013

Conditions
Heroin Addiction
Interventions
DRUG

Buprenorphine +OTP

Buprenorphine thrice weekly and counseling for four months while in pre-release prison, with referral for continued treatment at an opioid agonist treatment (OTP) program upon release. Such treatment lasts for 1 year in the community. Buprenorphine dosage, following an induction period,is 32 mg Mondays and Wednesdays and 48 mg Fridays

DRUG

Buprenorphine +CHC

Buprenorphine thrice weekly and counseling provided in pre-release prison for 4 months, with referral for continued treatment for 1 year in the community at a community health center (CHC). Following an induction period, buprenorphine dosing will be 32 mg on Mondays and Wednesdays and 48 mg on Fridays.

DRUG

Counseling +OTP

Counseling only for 4 months in pre-release prison, with referral upon release for buprenorphine treatment and counseling at an opioid agonist treatment program to last for 1 year. Following an induction period, buprenorphine dosing will be thrice weekly, with 32 mg on Mondays and Wednesdays and 48 mg on Fridays.

DRUG

Counseling +CHC

Counseling only for 4 months in pre-release prison, with referral upon release for buprenorphine treatment and counseling at a community health center to last for 1 year. Following an induction period, buprenorphine dosing will be thrice weekly, with 32 mg on Mondays and Wednesdays and 48 mg on Fridays.

Trial Locations (2)

20794

Maryland Correctional Institution for Women, Jessup

21201

Metropolitan Transition Center, Baltimore

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Friends Research Institute, Inc.

OTHER